Southern Research Institute is a 501(c)(3) organization based in Birmingham, Alabama, registered in 1945, with $50,381,130 in FY2024 revenue. CharityIndex grades it B+, and it directs about 70% of spending to programs.
Revenue (FY2024)
$50.4M
▲ 1.2% vs prior year
Science & Tech median: $288K
Expenses (FY2024)
$49.8M
Net assets
$181.6M
Employees
267
Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. For Southern Research Institute: 70% to programs · $0 to raise $100 earns a B on this criterion. See the exact thresholds →
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For Southern Research Institute: 44 mo reserves · +1% margin earns a A on this criterion. See the exact thresholds →
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. For Southern Research Institute: 5 of 6 checks met earns a A on this criterion. See the exact thresholds →
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For Southern Research Institute: 5 of 5 disclosure signals earns a A+ on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
To offer research & technology services to support industry and federal government agencies. to be operated for the benefit of the university of alabama at birmingham.
Cro services provides drug discovery and pre-clinical drug development to pharmaceutical and biotechnology on an outsourced basis. southern research institute has capabilities in all phases of the early-stage drug discovery and development process and provides clients with comprehensive services and support to assist them in streamlining their custom drug discovery and development programs. some of southern research institute's significant pre-clinical research accomplishments include: demonstrated the efficacy of combination chemotherapy in mice, leading the way for the development of therapeutic approaches with improved clinical outcomes in certain cancers, performed pre-clinical drug development evaluations and analyses on approximately half of the fda-approved cancer therapeutics currently on the market, and contributed to the development of the first drug delivery technology for the extended release of synthetic agents that promote the treatment of prostate cancer.
Southern research's stem education outreach program is involved in a wide variety of programs that impact students and teachers in alabama. the mission of sr's stem program is to enhance 6th through 12th grade stem education by drawing upon the expertise and scholarly contributions of the southern research community. we aim to define and exemplify effective stem education to maximize students' readiness to excel in a rapidly changing world. we are working to achieve our education mission by engaging students and teachers in stem activities through summer learning programs, field trips, after-school programing, stem competitions and science fairs, internships, and professional development workshops for stem educators. our primary objective is to embolden students who possess a passion for innovation and discovery to pursue their interests and strengthen the stem community. southern research is committed to fostering creativity and impacting the future generation.
Catalyst by southern research is a unique public health data system that connects patient genomes (and other forms of personalized medical data, potentially including transcriptomics, proteomics, metabolomics and others) to clinical data to support the health of communities. sr will accomplish this goal by investing infrastructure to (a) expand access to personalized medicine in alabama, especially in underserved areas of the state; (b) ensure alabamians have more effective diagnostics data to identify and treat underlying conditions and undetected co-morbidities that proved fatal for many alabamians during the covid-19 pandemic; and (c) enable greater access to clinical trials throughout the state. the catalyst program is designed to enhance and provide additioanl preventative care options to alabamians by (1) empowering individual with knowledge about their health; (2) connecting clinical and genomic data with local healthcare providers; and (3) encouraging participation in promising research via targeted clinical trials.
Revenue declined from $73.4M (FY2013) to $50.4M (FY2024) across 7 reported years.
Financial snapshot
Operating margin
1.1%
Revenue exceeded expenses in the latest fiscal year.
Total assets
$238.7M
Total liabilities
$57.2M
Net assets
$181.6M
Salaries & benefits
$24.8M
50% of expenses
Board members
14
10 independent
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2024 | $50,381,130▲1.2% | $49,830,156▼11.0% | $181,572,257▲1.5% | $238,738,191▼1.4% | 990 |
| 2023 | $49,759,960▼66.7% | $55,964,770▼2.0% | $178,870,874▼0.9% | $242,110,174▲14.6% | 990 |
| 2022 | $149,651,608▲74.7% | $57,118,873▼25.9% | $180,434,524▲95.9% | $211,179,645▲69.9% | 990 |
| 2021 | $85,654,710▲22.6% | $77,111,881▼8.3% | $92,089,720▼15.7% | $124,270,036▼14.2% | 990 |
| 2015 | $69,876,766▼14.0% | $84,126,126▼0.4% | $109,300,528▼10.6% | $144,792,189▼13.4% | 990 |
| 2014 | $81,265,192▲10.7% | $84,484,292▼1.7% | $122,242,513▼1.2% | $167,251,936▲3.1% | 990 |
| 2013 | $73,395,573 | $85,958,115▼3.1% | $123,676,222▼4.3% | $162,211,549▼3.3% | 990 |
| 2012 | — | $88,692,262▲2.6% | $129,299,091▼2.4% | $167,676,173▼1.7% | 990 |
| 2011 | — | $86,406,734▲0.2% | $132,455,488▲2.7% | $170,558,689▲3.1% | 990 |
| 2010 | — | $86,198,434 | $128,995,422 | $165,483,524 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Highest-paid: Joshua Carpenter — $412,848 (0.83% of total expenses)
| Name | Title | Hours/week | Compensation |
|---|---|---|---|
| Joshua Carpenter | President and Ceo (thru 12/24) | 40 | $412,848 |
| Oliver Hampton | Chief Data Officer | 40 | $383,042 |
| Corrine Augelli-szafran | Vp Scientific Platforms | 40 | $291,552 |
| David Rutledge | Senior Advisor of Finance | 40 | $253,474 |
| Khalilah Brown | Chief Medical Officer | 40 | $247,279 |
| Fusataka Koide | Director of Business Development | 40 | $241,585 |
| Monica W Mason | Interim Vp Cro Services | 40 | $238,113 |
| Harry Ledebur Jr | Chief Operating Officer | 40 | $232,271 |
| Lester Smith Jr | Chief Financial Officer (thru 6/24) | 40 | $227,390 |
| Anna Brantley Fry | Vp of People and Community (thru 6/24) | 40 | $211,854 |
| Marianne P Nurre | Sr. Controller | 40 | $201,521 |
| Jennifer Pickens | Director of Infectious Disease | 40 | $194,308 |
| Ricardo Brito | Chief of Staff | 40 | $187,879 |
| Abishek Kulshreshtha | Chief Business Officer (thru 3/24) | 40 | $144,437 |
| Ray Coleman Loper | Interim Ceo & Cfo | 32 | $104,434 |
| Anupam Agarwal | Director | 1 | — |
| Bobbie Knight | Director | 1 | — |
| Christopher S Brown Phd | Director | 1 | — |
| Finis St John VI | Director (thru 4/24) | 1 | — |
| Gene Ruffner Page Jr | Vice Chairman | 1 | — |
| Contractor | Services | Paid |
|---|---|---|
| Brasfield & Gorrie LLC | Construction and Engineering | $40,108,837 |
| Hm Southeast Concrete LLC | Construction and Engineering | $1,179,567 |
| Luckie and Company | Advertising | $614,023 |
| Allentown LLC | Manufacturing | $507,949 |
| Warren Averett | Accounting | $503,351 |
24 grants to Southern Research Institute totaling $8.8M, reported by foundations on their Schedule I filings — showing the 15 most recent.
| Grantmaker | Purpose | Year | Amount |
|---|---|---|---|
| Rockefeller Philanthropy Advisors Inc | Community improvement & capacity building, environment | 2024 | $25,000 |
| Family Health International | Clinical trials research | 2023 | $6,600 |
| Family Health International | Global health | 2022 | $39,603 |
| Michael J Fox Foundation For Parkinsons Research | Parkinson's research | 2021 | $133,097 |
| Family Health International | Global health | 2021 | $65,145 |
| Family Health International | Global health | 2020 | $54,645 |
| The Community Foundation of Greater Birmingham | General support | 2020 | $50,000 |
| Cystic Fibrosis Foundation | Therapeutics discovery research | 2019 | $2,198,738 |
| National Christian Charitable Foundation | Growth | 2019 | $100,000 |
| The Community Foundation of Greater Birmingham | General support + special programs | 2019 | $23,000 |
| Michael J Fox Foundation For Parkinsons Research | Parkinson's research | 2019 | $14,378 |
| Ayco Charitable Foundation | Community & human services | 2019 | $10,000 |
| Cystic Fibrosis Foundation | Therapeutics discovery research | 2018 | $2,431,262 |
| United Way of Greater St Louis Inc | Ccs designation-capacity building | 2018 | $26,304 |
| Cystic Fibrosis Foundation Therapeutics Inc | Therapeutics discovery | 2017 | $600,000 |
4 grants totaling $26K in FY2015. All grants made by Southern Research Institute →
| Recipient | Purpose | Amount |
|---|---|---|
| United Way of Central Alabama Inc | General support | $10,000 |
| Holy Family Cristo Rey Catholic High School | General support | $6,400 |
| American Cancer Society Inc | General support | $5,000 |
| The Economic Development Partnership of Alabama Inc | General support | $5,000 |
Explore more
Data for Southern Research Institute (EIN 63-0288868) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.